|Table of Contents|

Expression of CCND1 in human osteosarcoma tissue

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2022 04
Page:
566-569
Research Field:
Publishing date:

Info

Title:
Expression of CCND1 in human osteosarcoma tissue
Author(s):
CAI Chengkui1; TIAN Liying2; MA Qiong3; MA Baoan3
1.Department of Orthopedics,the Second Affiliated Hospital of Shaanxi University of Chinese Medicine,Shaanxi Xianyang 712000,China;2.Department of Anesthesiology;3.Department of Orthopedics,the Second Affiliated Hospital of Air Force Medical University,Shaanxi Xi' an 710038,China.
Keywords:
osteosarcoma; CCND1; immunohistochemistry; real-time quantitative PCR
PACS:
R738.1
DOI:
10.3969/j.issn.1672-4992.2022.04.002
Abstract:
Objective:To investigate the role of cyclin D1 (CCND1) in the occurrence and development of osteosarcoma by detecting the change of the expression of the CCND1 in osteosarcoma tissue.Methods:The difference of CCND1 expression between osteosarcoma tissue and peritumoral tissue was detected by immunohistochemistry,and the mRNA expression of CCND1 was detected by real-time quantitative PCR,and the similarities and differences between the two experimental results were compared.Results:The result of immunohistochemistry experiment showed that the expression of CCND1 in osteosarcoma tissue was higher than that in the peritumoral tissue,and the difference was statistically significant (P＜0.05).Real-time quantitative PCR result further showed that the mRNA expression of CCND1 in osteosarcoma tissue was 2.55 times higher than that in the peritumoral tissue,and the difference was statistically significant (P＜0.05).Conclusion:The results of the two experiments showed that the expression of CCND1 increased in osteosarcoma tissue,which indicate that CCND1 was up-regulated in osteosarcoma tissue.

References:

[1]JONES KB,SALAH Z,DEL MARE S,et al.miRNA signatures associate with pathogenesis and progression of osteosarcoma［J］.Cancer Res,2012,72:1865-1877.
[2] OTTAVIANI G,JAFFE N.The epidemiology of osteosarcoma［J］.Cancer Treat Res,2009,152:3-13.
[3]SMITH MA,ALTEKRUSE SF,ADAMSON PC,et al.Declining childhood and adolescent cancer mortality［J］.Cancer,2014,120:2497-2506.
[4]HARRIS MB,GIESER P,GOORIN AM,et al.Treatment of metastatic osteosarcoma at diagnosis:a Pediatric Oncology Group Study［J］.J Clin Oncol,1998,16:3641-3648.
[5] KAGER L,ZOUBEK A,PTSCHGER U,et al.Primary metastatic osteosarcoma:presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols［J］.J Clin Oncol,2003,21:2011-2018.
[6]ALJUBRAN AH,GRIFFIN A,PINTILIE M,et al.Osteosarcoma in adolescents and adults:survival analysis with and without lung metastases［J］.Ann Oncol,2009,20:1136-1141.
[7]MIALOU V,PHILIP T,KALIFA C,et al.Metastatic osteosarcoma at diagnosis:prognostic factors and long-term outcome-the French pediatric experience［J］.Cancer,2005,104:1100-1109.
[8] GELLER DS,GORLICK R.Osteosarcoma:a review of diagnosis,management,and treatment strategies［J］.Clin Adv Hematol Oncol,2010,8:705-718.
[9] SHERR CJ.D-type cyclins［J］.Trends Biochem Sci,1995,20:187-190.
[10]MOTOKURA T,BLOOM T,KIM HG,et al.A novel cyclin encoded by a bell-linked candidate oncogene［J］.Nature,1991,350:512-515.
[11] LIU Q,FU H,SUN F,et al.miR-16-1 family induces cell cycle arrest by regulating multiple cell cycle genes［J］.Nucleic Acids Res,2008,36:5391-5404.
[12] SANTARIUS T,SHIPLEY J,BREWER D,et al.A census of amplified and overexpressed human cancer genes［J］.Nat Rev Cancer,2010,10:59-64.
[13] ZHANG H.CCND1 silencing suppresses liver cancer stem cell differentiation through inhibiting autophagy［J］.Hum Cell,2020,33(1):140-147.
[14]LI C,GE M,CHEN D,et al.RPL21 siRNA blocks proliferation in pancreatic cancer cells by inhibiting DNA replication and inducing G1 arrest and apoptosis［J］.Front Oncol,2020,10:1730.
[15]GAUTSCHI O,RATSCHILLER D,GUGGER M,et al.Cyclin D1 in non-small celllung cancer:a key driver of malignant transformation［J］.Lung Cancer,2007,55:1-14.
[16]HUANG SR,JIN SS,XU B,et al.Puerarin alleviates the progression of non-small cell lung cancer by regulating the miR-342/CCND1 axis［J］.Neoplasma,2020,67(6):1244-1255.
[17]MONTAUDON E,NIKITOROWICZ-BUNIAK J,SOURD L,et al.PLK1 inhibition exhibits strong anti-tumoral activity in CCND1-driven breast cancer metastases with acquired palbociclib resistance［J］.Nat Commun,2020,11(1):4053.
[18]WANG X,WANG C,YAN G,et al.BAP18 is involved in upregulation of CCND1/2 transcription to promote cell growth in oral squamous cell carcinoma［J］.EBioMedicine,2020,53:102685.
[19] THOMAS GR,NADIMINTI H,REGALADO J.Molecular predictors of clinical outcome in patients with head and neck squamous cell carcinoma［J］.International Journal of Experimental Pathology,2005,86:347-363.
[20]GONZLEZ-RUIZ L,GONZLEZ-MOLES M,GONZLEZ-RUIZ I,et al.An update on the implications of cyclin D1 in melanomas［J］.Pigment Cell Melanoma Res,2020,33(6):788-805.
[21] YING Y,LI J,XIE H,et al.CCND1,NOP14 and DNMT3B are involved in miR-502-5p-mediated inhibition of cell migration and proliferation in bladder cancer［J］.Cell Prolif,2020,53(2):e12751.
[22] MORENO-BUENO G,RODRIGUEZ-PERALES S,SANCHEZ-ESTEVEZ C,et al.Molecular alterations associated with cyclin D1 overexpression in endometrial cancer［J］.International Journal of Cancer,2004,110:194-200.
[23]YU L,YE F,LI YY,et al.Histone methyltransferase SETDB1 promotes colorectal cancer proliferation through the STAT1-CCND1/CDK6 axis［J］.Carcinogenesis,2020,41(5):678-688.

Memo

Memo:
National Natural Science Foundation of China(No.81201633）；国家自然科学基金项目（编号：81201633）
Last Update: 1900-01-01